PT  - JOURNAL ARTICLE
AU  - Alexander Stäuber
AU  - Cornelia Piper
AU  - Marco Köster
AU  - Marcus Dörr
AU  - Stefan Richter
AU  - Marc-Alexander Ohlow
AU  - Siegfried Eckert
AU  - Johannes Baulmann
TI  - Invasive validation of the Antares algorithm for determining central blood pressure based on upper arm oscillometric pulse waves in patients with type 2 diabetes
AID  - 10.1136/bmjdrc-2022-003119
DP  - 2023 Jan 01
TA  - BMJ Open Diabetes Research & Care
PG  - e003119
VI  - 11
IP  - 1
4099  - http://drc.bmj.com/content/11/1/e003119.short
4100  - http://drc.bmj.com/content/11/1/e003119.full
SO  - BMJ Open Diab Res Care2023 Jan 01; 11
AB  - Introduction Antares is a pulse wave analysis (PWA) algorithm designed to allow a non-invasive estimation of central (aortic) blood pressure (cBP) using automated oscillometric blood pressure (BP) devices. Diabetes may affect elastic and muscular arteries differently, resulting in disparate pulse wave characteristics in central and peripheral arteries, which may limit the accuracy of PWA devices. The aim of our study was to evaluate the accuracy of Antares for estimating cBP as compared with invasively measured cBP in patients with type 2 diabetes.Research design and methods In this study, consecutive patients undergoing elective coronary angiography were recruited between November 2017 and September 2020. In 119 patients with type 2 diabetes, cBP was measured invasively and simultaneously determined non-invasively using the custo screen 400 device with the integrated Antares algorithm.Results The mean difference between the estimated and invasively measured cBP was 1.2±6.3 mmHg for central systolic BP (cSBP), 1.0±4.3 mmHg for central mean arterial pressure (cMAP) and 3.6±5.7 mmHg for central diastolic BP (cDBP). High correlations were found between estimated cBP and invasively measured cBP (cSBP: r=0.916; cMAP: r=0.882; cDBP: r=0.791; all p<0.001).Conclusions The present study suggests that the Antares algorithm incorporated into the custo screen 400 device can estimate cBP with high accuracy turning a conventional oscillometric BP device into a type II device for the non-invasive estimation of cBP, which is applicable in patients with type 2 diabetes. Integration of Antares into commercially available BP devices could facilitate the introduction of cBP into routine clinical practice as a part of disease and risk management.Data are available on reasonable request. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.